18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
M.D. Anderson Cancer Center
Summary
To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.
Description
Primary Objectives * Evaluate the ability of 18F-FAraG PET imaging to detect tumors in participants with esophageal cancer; * Evaluate 18F-FAraG PET as a predictor of pathologic complete response Secondary Objectives * Evaluate the correlation of 18F-FAraG PET with clinical characteristics * Evaluate the correlation of 18F-FAraG PET with scRNA-seq data * Evaluate tissue and blood biomarkers as predictors of treatment response and disease recurrence * Evaluate functional imaging with 18F-FAraG PET and tissue and blood biomarkers as predictors of overall survival and disease-free survival * C…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Participants must be ≥18 years of age 2. Participants with locally advanced esophageal cancer 3. Participants with untreated documented carcinoma of the esophagus that is \> 2 cm in patients who are going to receive systemic therapy concurrently with radiation as primary therapy are eligible 4. Ability to provide written informed consent in accordance with institutional policies 5. Female participants of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investi…
Interventions
- DrugArabinoFuranosylGuanine [18F]F-AraG
Given by IV
Location
- MD Anderson Cancer CenterHouston, Texas